Natco Pharma approves ₹1,279 crore rights issue at ₹750 per share
As filed · Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : 21, i.e 2 Equit
What happened
FactNatco Pharma’s Board approved a rights issue of 1,70,58,082 equity shares at ₹750 per share, aggregating to ₹12,79,35,61,500 assuming full subscription. The issue will offer 2 rights shares for every 21 shares held, with October 1, 2026 as the record date and the issue open from October 12 to October 22, 2026.
Why it matters
CapitSignal interpretationExisting holders can maintain their stake only by putting in more money; those who do not subscribe are diluted.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
RevisedI think we will end the year with another extra Rs 250 to 300 crores of extra PAT we were expecting.
So, we expect the cash will be around maybe Rs 2,700 crores, 2,800 crores is what we are expecting a cash will settle around.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Rights ratio and issue price
- Record date and subscription window
- Promoter intention to subscribe
- I think we will end the year with another extra Rs 250 to 300 crores of extra PAT we were expecting. (management committed by FY25)
- So, we expect our run rate to be around Rs 750 to 800 crores of revenue, and a PAT should be around Rs 135 to (management committed by H1 FY25)
Evidence
- Natco Pharma Limited has informed the Exchange about issue of Securities on Rights Basis(opens the original filing in a new tab)
- Earlier statement · Q2 FY25
- Latest statement · Q2 FY25
- Earlier statement · Q2 FY25
How CapitSignal classified this
- Reasoning:
- The approved fundraise could increase the company’s outstanding shares by approximately 9.52% if fully subscribed, creating potential dilution for shareholders who do not participate. The filing does not state the intended use of the proceeds, and final allotment remains subject to the basis of allotment.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%